New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO ® (lanadelumab-flyo) injection in patients with hereditary angioedema (HAE) 12 years of age and older studied in the ongoing Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses, being presented at the 2019 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting in Houston, Texas from November 7-11, showed that TAKHZYRO continued to prevent HAE attacks at a rate similar to that observed in the pivotal HELP Study, in patients who received treatment for a mean duration of 19.7 (0-26.1) months.1, 2 The analyses will also be published in the November issue of ACAAI’s journal Annals of Allergy, Asthma & Immunology.
The original Phase 3 HELP Study was conducted in 125 patients over 26 weeks making it the largest randomised, controlled prevention study in HAE, with the longest active treatment duration, to date.3 The ongoing HELP Study OLE is designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO and is expected to be completed in November 2019. These analyses included 109 rollover patients, who were originally evaluated in the HELP Study, and 103 eligible non-rollover patients who did not participate in the initial study but had experienced at least one attack in 12 weeks.1, 2, 4
Results from the HELP Study OLE showed that the safety profile of TAKHZYRO was consistent with the original findings from the HELP Study, with treatment-related treatment emergent adverse events (TEAEs) occurring in 50% of patients (n=106).2 In addition, TAKHZYRO 300 mg every 2 weeks reduced the rate of attacks, attacks requiring acute treatment, and moderate to severe attacks (secondary efficacy endpoints). The mean attack rate was reduced by 87% overall compared with baseline (N=212). Similarly there was an overall reduction of 92.6% in the rate of attacks requiring acute treatment (N=212) and 83.6% in the rate of moderate/severe attacks versus baseline (N=212).1 An exploratory analysis showed that the overall maximum attack-free period lasted ≥12 months in 58% of patients (n=209) and ≥6 months in 78% of patients (n=209) following the first regular treatment dose.1
“While the original HELP Study data has given us a strong understanding of how TAKHZYRO can prevent HAE attacks, the results of these analyses provide encouraging insight into its potential safety and efficacy over a longer duration,” said Marc A. Riedl, M.D., investigator in the HELP Study OLE and Professor of Medicine and Clinical Director, U.S. Hereditary Angioedema Association Center at the University of California, San Diego. “As HAE is a lifelong condition, the long-term efficacy and safety of prophylactic medications are important factors in developing individualized HAE management plans. The HELP Study OLE analyses are a positive step forward in understanding the long-term effects of TAKHZYRO, and we look forward to gathering and sharing additional data as the study progresses.”
In the study, TEAEs occurred in ~95% of patients (N=212) and were mostly mild or moderate in severity. The TEAEs related to treatment that were reported in more than 5% of patients are injection site pain (33.9% of rollover patients [n=37] and 42.7% of non-rollover patients [n=44]), injection site erythema (11.9% of rollover patients [n=13] and 15.5% of non-rollover patients [n=16]) and injection site bruising (4.6% of rollover patients [n=5] and 9.7% of non-rollover patients [n=10]).2
TEAEs of special interest were reported in eight (3.8%) patients; none were serious. Six (2.8%) patients discontinued from the study due to TEAEs, one of which was treatment related (injection site papules). No treatment related, serious TEAEs or deaths occurred. Anti-lanadelumab antibodies were detected in 21 (9.9%) patients, including six (2.8%) positive for neutralizing antibodies with no discernible clinical impact.2
“Recurrent and unpredictable attacks of swelling can be debilitating and impact those living with HAE in a number of ways,” said Donatello Crocetta, M.D., Global Medical Head, Rare Immunology Franchise, Chief Medical Office, Takeda. “Over the last 10 years, we have been committed to continuous innovation in HAE to help address patients’ unmet treatment needs. These findings build on our knowledge about HAE and are valuable in better understanding the benefits that preventive treatment with TAKHZYRO could bring to patients in the longer term.”
Details on the HELP Study OLE abstracts being presented are as follows:
Long-Term Efficacy of Lanadelumab: Interim Results from the HELP OLE Study Abstract #P1591
- Friday, 8 November, 5:15-5:30pm
Long-Term Safety of Lanadelumab in Hereditary Angioedema (HAE): Interim Results From the HELP OLE Study Abstract #P1582
- Friday, 8 November, 5:00-5:15pm
Long-Term Lanadelumab Treatment Improves Health-related Quality of Life: HELP OLE Study Interim Findings Abstract #P1564
- Friday, 8 November, 4:30-4:45pm
About The HELP Study™ Open-label Extension
The HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE) is an evaluation of the long-term efficacy and safety of TAKHZYRO in hereditary angioedema (HAE) patients of at least 12 years of age and older. Two hundred and twelve patients received treatment with TAKHZYRO at the start of the OLE Study (109 rollover patients originally evaluated in the HELP Study and who continued into the OLE, and 103 eligible patients who did not participate in the HELP study but who had experienced at least one attack in 12 weeks). Rollover patients received a dose of 300 mg TAKHZYRO on Day 0 and then every two weeks after their first attack. Non-rollover patients were treated with one 300 mg dose every two weeks, beginning on Day 0. One hundred and ninety-three participants completed at least 12 months of treatment and 27 participants completed at least 24 months of treatment.1, 2
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disorder that results in recurring attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat. The swelling can be debilitating and painful.5, 6, 7 Attacks that obstruct the airways can cause asphyxiation and are potentially life threatening.6, 7 HAE affects an estimated 1 in 10,000 to 1 in 50,000 people worldwide. It is often under-recognized, under-diagnosed and under-treated.5, 8
About TAKHZYRO® (lanadelumab-flyo) Injection
TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein and is indicated for prophylaxis to prevent HAE attacks in patients 12 years and older. TAKHZYRO is formulated for subcutaneous administration and has a half-life of approximately two weeks.9 TAKHZYRO is intended for self-administration or administration by a caregiver. The patient or caregiver should be trained by a healthcare professional.9
U.S. Indication and Important Safety Information
TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.9
IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.9
Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.9
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.9
No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.9
To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-828-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For U.S. audiences, please see the full Prescribing Information including Medication Guide for TAKHZYRO®.
For EU audiences, please see the Summary of Product Characteristics (SmPC) for TAKHZYRO®.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
1 Riedl MA, Cicardi M, Hao J, et al; for the HELP OLE Study Investigators. Long-Term Efficacy of Lanadelumab: Interim Results from the HELP Open-Label Study. ACAAI 2019. Abstract #P159.
2 Johnston DT, Banerji A, Nurse C, et al; for the HELP OLE Study Investigators. Long-Term Safety of Lanadelumab in Hereditary Angioedema (HAE): Interim Results From the HELP OLE Study. ACAAI 2019. Abstract #P158.
3 Banerji A, Riedl MA, Bernstein JA, et al; for the HELP Investigators. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.
4 Lumry WR, Maurer M, Megerl M, et al; for the HELP OLE Study Investigators. Long-term Lanadelumab Treatment Improves Health-related Quality of Life: HELP Open-label Extension Study Interim Findings. ACAAI 2019. Abstract #P156.
5 Cicardi M, Bork K, Caballero T, et al; on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012; 67(2):147-157.
6 Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
7 Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-336.
8 Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations, and treatment. Br J Hosp Med. 2006;67(12):654-657.
9 TAKHZYRO ® (lanadelumab) Summary of Product Characteristics.
+81 (0) 3-3278-2095
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ZMC Partners With CommentSold11.11.2019 17:00:00 CET | Press release
CommentSold, Inc. (“CommentSold” or the “Company”) today announced that affiliates of private equity firm ZMC have invested in the Company. Terms of the transaction were not disclosed. Founded in 2017 by CEO Brandon Kruse, CommentSold is a leading provider of multi-channel social commerce technology and managed services to boutique online retailers. The Company provides a variety of commerce enablement services including order intake, payment, fulfillment, live selling tools and analytics which are delivered through a proprietary SaaS platform, allowing customers to sell on social platforms and mobile apps. Mr. Kruse will continue as Chief Executive Officer of the Company. “ZMC’s investment will enable CommentSold to continue to offer best in class services, support, and technology for its growing community of retailers,” said Mr. Kruse. “CommentSold will benefit from ZMC’s active involvement and leadership as we continue to grow our customer base, enhance our technology and expand our
GA-ASI to Conduct Series of Capability Demonstrations in Europe11.11.2019 17:00:00 CET | Press release
General Atomics Aeronautical Systems, Inc. (GA-ASI), a global leader in Remotely Piloted Aircraft (RPA), announced today that they are working with the Hellenic Air Force (HAF) in Greece to conduct a series of demonstration flights for European countries in December. Flights will base out of the HAF’s site in Larissa and use a GA-ASI MQ-9 Guardian RPA to showcase maritime surveillance capabilities, as well as a GA-ASI-developed Detect and Avoid (DAA) system that enables RPA to fly safely in civil airspace alongside manned aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191111005503/en/ “We appreciate the Hellenic Air Force’s support in helping showcase the maritime surveillance and civil airspace integration capabilities of our unmanned aircraft in Europe.” - Linden Blue, CEO, GA-ASI. (Photo: Business Wire) “We appreciate the HAF’s support in helping showcase the maritime surveillance and civil airspace integration
Novarica Market Navigator Report Validates FINEOS is the Market Leader in Life, Accident and Health Claims Systems in North America By Client Base11.11.2019 14:20:00 CET | Press release
FINEOS Corporation (ASX: FCL), the leading core insurance platform vendor for life, accident and health (LA&H), was profiled in the recent Novarica Market Navigator Life/Health Claims Systems (September 2019). The report shows FINEOS has the largest client base for LA&H Claims in North America covering both individual and group markets. The Novarica Market Navigator report provides an overview of available stand-alone claims systems for Life, Accident & Health insurers. FINEOS was profiled across a wide range of criteria including functionality, technology, differentiators and implementation capabilities as shown in this report excerpt. The report found that claims gained ground as one of the most critical capabilities an insurer needs to meet heightened customer expectations to match service levels provided across all types of business including retailers and financial services. Additional findings reveal that advanced claims processing capabilities like triage-based STP, skill-based
The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPD11.11.2019 13:30:00 CET | Press release
Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that the 2020 update from the Global Initiative for Chronic Obstructive Disease (GOLD) has upgraded the evidence level rating for bronchoscopic lung volume reduction (BLVR) with endobronchial valves, including the Zephyr Valve, for the treatment of emphysema / chronic obstructive pulmonary disease (COPD). In the newly released report, GOLD upgraded the evidence rating to “A”, the highest evidence rating, for BLVR with endobronchial valves.1 This evidence rating is based on results from well-designed randomized clinical trials with data from more than two clinical trials involving a substantial number of patients, including those treated with the Zephyr Valve. The Zephyr Valve is a minimally-invasive treatment option that has been shown to improve quality of life of emphysema patients by allowing them to experience less shortness of breath and be more active.2 This press release features multimed
TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies11.11.2019 13:26:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced 24-week Phase 3 data showing a significantly greater proportion of patients with active psoriatic arthritis (PsA) treated with TREMFYA® ▼ (guselkumab) achieved at least a 20 percent improvement in disease signs and symptoms (American College of Rheumatology ACR20 response) compared to placebo.1,2 These findings represent the primary endpoints of the DISCOVER-1 and DISCOVER-2 Phase 3 studies, which were designed to evaluate the efficacy and safety of investigational use of guselkumab for the treatment of adult patients with active PsA.1,2 These results were presented as part of an oral plenary session (abstract 0807) and a late-breaking poster session (abstract L13), respectively, at the American College of Rheumatology and Association of Rheumatology Professionals (ACR/ARP) 2019 Annual Meeting taking place 8-13 November in Atlanta.1,2 Janssen presented a total of 30 abstracts at the meeting. “People living with p
Wipro Implements SAP S/4HANA® for Sydney Water11.11.2019 12:55:00 CET | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the successful implementation of SAP S/4HANA® software for Sydney Water, a statutory state-owned corporation wholly owned by the New South Wales Government. Wipro has also integrated modules of Industry-Specific Solution for the Utilities Industry (IS-U), Customer Relationship Management (CRM) and Flexible Real Estate Management (RE-FX) globally for the customer. Leveraging SAP S/4HANA, Sydney Water will be able to deploy state-of-the-art features in its billing and customer services, enabling simplified billing processes and next-generation transformation of customer self-service. Built with additional capabilities such as holistic view of customer data and intelligent mobile-based interaction, this solution will provide end users with an interactive interface. It will enable a 360-degree view of the customer, resulting in incre